



ASX Release

26 September 2022

Receipt of R&D Tax Incentive Rebate

Melbourne, Australia; 26 September 2022

Acrux Limited (ASX:ACR) is pleased to announce the receipt of \$983,421.89 from the Australian Tax Office in relation to its R&D Tax Incentive Rebate for the 2021/2022 financial year for one of its subsidiary companies. The Company expects to receive an additional R&D tax incentive rebate in the near term for another subsidiary company.

Additionally, AusIndustry has favourably assessed our application for an Overseas Finding and has determined certain expenditure in relation to overseas activities conducted through this period to be eligible for the R&D Tax Incentive Rebate. An additional claim will be made for these eligible overseas activities.

The R&D Tax Incentive is an Australian Federal Government program under which companies receive cash refunds for eligible research and development expenditure.

Authorised for release by the Board of Acrux Limited.

For more information, please contact:

Michael Kotsanis

Acrux Limited

CEO & Managing Director

P: + 61 3 8379 0100

E: michael.kotsanis@acrux.com.au

About Acrux

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising topical pharmaceuticals. Drawing on 25 years of experience and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of topically applied pharmaceutical products in the US and Europe. Acrux is developing of a range of generic products for the US market by leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit www.acrux.com.au